Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting comprising approval of Unaudited Financial Results and a Scheme of Amalgamation
Audit Opinion:
The statutory auditors, Deloitte Haskins & Sells, issued an unmodified conclusion on the limited review for both the standalone and consolidated financial results for the quarter ended June 30, 2026.
Key Financial Highlights [All amounts in ₹ million]
Standalone Results:
- Revenue from Operations: ₹27,995.1 (Q1 FY26: ₹28,481.7; Q4 FY26: ₹27,865.5)
- Total Income: ₹30,414.0 (Q1 FY26: ₹29,319.4; Q4 FY26: ₹30,006.4)
- Net Profit: ₹7,372.2 (Q1 FY26: ₹5,591.3; Q4 FY26: ₹6,922.3)
- EPS (Basic & Diluted): ₹12.75 (Not annualised) (Q1 FY26: ₹9.63; Q4 FY26: ₹11.92)
- Other Equity: ₹226,596.1 (as of March 31, 2026)
- Paid-up equity share capital: ₹575.4 (face value ₹1 per share)
Consolidated Results:
- Revenue from Operations: ₹91,503.5 (Q1 FY26: ₹78,681.4; Q4 FY26: ₹88,533.4)
- Total Income: ₹94,145.8 (Q1 FY26: ₹79,734.4; Q4 FY26: ₹89,703.8)
- Profit before tax: ₹15,150.9 (Q1 FY26: ₹12,068.0; Q4 FY26: ₹12,906.1)
- Profit after tax: ₹10,320.3 (Attributable to owners of the parent: ₹10,325.6)
- EPS (Basic & Diluted): ₹17.86 (Not annualised) (Q1 FY26: ₹14.20; Q4 FY26: ₹15.86)
- Other Equity: ₹378,328.9 (as of March 31, 2026)
- Paid-up equity share capital: ₹575.4 (face value ₹1 per share)
Segment-wise Performance:
The Company and the Group operate in only one reportable segment, 'Pharmaceuticals', as per Ind AS 108.
Corporate Actions:
- The Board approved a proposal to file a Scheme of Amalgamation for the merger of Eugia Steriles Private Limited and Eugia SEZ Private Limited (wholly owned step-down subsidiaries) with Eugia Pharma Specialities Limited (a wholly owned subsidiary). The scheme will be filed with the Hon'ble NCLT, Hyderabad.
- The buyback of 5,423,728 equity shares (0.93% of capital) at a maximum price of ₹1,475 per share for an aggregate value not exceeding ₹8,000.0 million was completed. The aggregate amount paid was ₹8,065.3 million including expenses, reducing paid-up capital by ₹5.4 million.
- The transfer of the domestic branded generic formulations business to Auropharm Limited (a wholly owned subsidiary) was completed on April 1, 2026, for a consideration of ₹1,432.1 million.
Other Significant Information:
Acquisitions and Investments:
- On June 29, 2026, the company completed the acquisition of 100% membership interest in Lannett Company LLC (including subsidiaries Silarx Pharmaceuticals Inc, Kremers Urban Pharmaceuticals Inc, and Cody Laboratories Inc) for a purchase consideration of ₹23,348.8 million (USD 247.1 million). Acquisition and related costs of ₹401.8 million (USD 4.3 million) were recorded as an exceptional item.
- The company incorporated a step-down subsidiary, Arrow Pharma Production SAS, France, through Agile Pharma B.V., Netherlands, effective May 21, 2026.
- The company invested ₹5.2 million to acquire a 26% stake in Swarnaakshu Solar Power Private Limited, making it an associate effective June 25, 2026.
- The company incorporated a step-down subsidiary, PT Auro Pharm Indonesia, through PT Aurogen Pharma Indonesia, effective July 1, 2026.
- Subsequent to the quarter end (July 23, 2026), the board of Apitoria Pharma Private Limited (a wholly owned subsidiary) approved the acquisition of an 80% ownership interest in the A1 Biochem Group at an enterprise value of USD 17.0 million. The company will invest USD 13.6 million.
Exceptional Items:
- Consolidated results include an exceptional item of ₹401.8 million for Lannett acquisition costs.
- A note references an incremental cost of ₹173.8 million (standalone) and ₹653.3 million (consolidated) recognized during FY26 due to the implementation of New Labour Codes, effective from November 21, 2025.
Other Expenses:
- Aurobindo Pharma USA, Inc. recorded a net loss on derecognition of lease receivable of ₹432.6 million (USD 4.5 million), included under 'Other expenses'.
Entities in Consolidation:
The review report annexure lists 102 entities (subsidiaries, joint ventures, and associates) included in the consolidation.